11/19
11:41 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Medium
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
11/19
08:00 am
orka
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Medium
Report
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
11/13
06:05 pm
orka
Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 [Seeking Alpha]
High
Report
Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 [Seeking Alpha]
11/13
04:29 pm
orka
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/13
04:25 pm
orka
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/4
07:00 am
orka
Oruka Therapeutics to Present at Multiple November Investor Conferences
Low
Report
Oruka Therapeutics to Present at Multiple November Investor Conferences
10/31
08:35 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
High
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
10/11
08:07 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $49.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $49.00 price target on the stock.
10/7
08:17 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $45.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $45.00 price target on the stock.
9/25
07:13 am
orka
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress [Yahoo! Finance]
Low
Report
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress [Yahoo! Finance]
9/25
07:08 am
orka
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Low
Report
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
9/18
07:31 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/17
08:18 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $44.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $44.00 price target on the stock.
9/16
10:09 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $41.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $41.00 price target on the stock.
9/16
08:03 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
9/13
07:59 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.
9/12
07:05 am
orka
Oruka Therapeutics Announces $200 Million Private Placement
High
Report
Oruka Therapeutics Announces $200 Million Private Placement
9/12
07:00 am
orka
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
High
Report
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
9/5
10:25 am
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Medium
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Wedbush to a "strong-buy" rating.
9/4
02:05 pm
orka
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Wedbush. They set an "outperform" rating and a $40.00 price target on the stock.
Low
Report
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Wedbush. They set an "outperform" rating and a $40.00 price target on the stock.
9/3
07:00 am
orka
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
High
Report
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million